October 2018- Volume 14, Issue 10
In this Issue
Preclinical
Peering into the preclinical realm
Peering into the preclinical realm
A roundup of recent preclinical data presentations and journal publications
Possibility grows for pan-Ebola vaccine
Possibility grows for pan-Ebola vaccine
Scripps team discovers potential target mechanisms that could enable the treatment of multiple strains of Ebolavirus
More coverage on Coversin
More coverage on Coversin
Akari reports on the effects of its bimodal Coversin in inflammatory indications
FR104 offers control of graft-versus-host disease
FR104 offers control of graft-versus-host disease
OSE Immunotherapeutics’ study of the CD28 antagonist was published in Journal of Clinical Investigation
Clinical Trials
Effective option for the skin
Effective option for the skin
Clinical trial shows monoclonal antibody drug effective against pruritus
Dupixent delivers strong Phase 3 results
Dupixent delivers strong Phase 3 results
Patients saw improvements in skin clearing and quality of life
Out of the starting gate
Out of the starting gate
A roundup of clinical trial startups and initial breakthroughs
Diagnostics
Diagenode snaps up NXT-Dx
Diagenode snaps up NXT-Dx
The transaction expands Diagenode’s epigenetics and epigenomics offerings
‘A clear benefit’
‘A clear benefit’
Agena, PerkinElmer partnership emphasizes quality, speed and sensitivity in liquid biopsy
It’s all in the volume measurement
It’s all in the volume measurement
Data show Daxor’s BVA-100 is superior to formula-based estimates of blood volume in assessing heart failure patients
A ‘breakthrough biomarker’ for rheumatoid arthritis
A ‘breakthrough biomarker’ for rheumatoid arthritis
Novel test now available to aid in detection and management of debilitating condition
Discovery
Say yes to YRSACT
Say yes to YRSACT
Scripps scientists find new lead to combat low platelet counts
Infectious disease research reaches across borders
Infectious disease research reaches across borders
New collaboration announced between Boehringer Ingelheim and Tsinghua University
Getting together
Getting together
A roundup of recent discovery-related deals and agreements
AI, drug discovery and rare disease
AI, drug discovery and rare disease
Pharma executive Kate Hilyard joins Healx to drive integration effort forward
A new answer for amoeba treatment
A new answer for amoeba treatment
Skaggs researchers from UCSD repurpose approved drugs to treat fatal brain infection
Contract Services
Partnering for efficiency
Partnering for efficiency
Companies collaborate on cloud-based IT validation software for life sciences
Building better models
Building better models
CrownBio licenses translational breast cancer models of resistance and metastasis
Extending the value
Extending the value
CRO announces $7.8M extension agreement for OmniComm’s TrialOne
Research & Development
Bispecific boon
Bispecific boon
Aptevo will use Genedata platform to streamline cancer immunotherapy R&D
More than just skin
More than just skin
Otezla post-hoc sub-analyses showed meaningful improvements in metrics beyond skin clearance
Welcome to the real world
Welcome to the real world
PAREXEL and Datavant partner to enhance drug development and commercialization
Transcription factors and TransSyn
Transcription factors and TransSyn
Multicenter European team reveals computational method for predicting how to convert subpopulations of cells
All in the epigenetics
All in the epigenetics
Team finds epigenetic reason for drug resistance in deadly melanoma and identifies potential ways to counteract it
Business & Government Policy
Boehringer Ingelheim acquires all ViraTherapeutics shares
Boehringer Ingelheim acquires all ViraTherapeutics shares
The German company seeks to develop next-generation viral-based immuno-oncology therapies
BIA Separations expands
BIA Separations expands
New lab processing facility will support integrated optimization of upstream and downstream process development
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
VistaGen acquires worldwide license of phase 3-ready CNS drug
VistaGen acquires worldwide license of phase 3-ready CNS drug
Candidate from Pherin Pharmaceuticals is meant for as-needed treatment of social anxiety disorder
Special Reports
Special Report on Cell Biology: Well CHOsen?
Special Report on Cell Biology: Well CHOsen?
Ever more complicated biologics push technical boundaries
Editor's Focus
Editor’s focus: The struggle against schizophrenia
Editor’s focus: The struggle against schizophrenia
Therapeutics for mental illness have always been tricky, but schizophrenia seems a bit more intractable than most
Commentary
New recruits for 2019
New recruits for 2019
Opportunities for Ph.D. students entering the workforce go beyond just academia
Guest Commentary: Bringing precision medicine to the evaluation and treatment of mental illness
Guest Commentary: Bringing precision medicine to the evaluation and treatment of mental illness
What we do know about the genetics, neurobiology and behavioral science of mental illness can be used to improve diagnosis and treatment
Feature
Society for Neuroscience Annual Meeting Show Preview: Taking notice of the neurological
Society for Neuroscience Annual Meeting Show Preview: Taking notice of the neurological
SfN annual meeting gets ready for networking, the most recent neurological research and the newest neuroscience
Focus Feature on Breast Cancer
Focus Feature on Breast Cancer
Beginning with a story about Salk researchers finding a ‘master control switch' for aggressive breast cancer, we give you a quick roundup of recent breast cancer news in honor of Breast Cancer Awareness Month
